ATRA Gad Soffer bought Atara Biotherapeutics, Inc. shares — SEC Form 4BUYAtara Biotherapeutics, Inc.

The stock has rallied 9.36% over the past 30 days and is currently trading 51.16% below its 52-week high of $19.15, having recently experienced an 82% surge in May after the FDA outlined a regulatory pathway for tab-cel.

• •Q4 Earnings on March 16, 2026: The company reported a loss of $3.4 million (25 cents per share) and revenue of $1.6 million in the prior quarter.
• •FDA Resubmission Path for Tab-cel: The FDA outlined a potential pathway for resubmitting the tabelecleucel application following a recent Complete Response Letter.
• •Largest Ever Insider Purchase: A single insider executed the largest purchase in the company's history, a signal of high conviction.

• •High Short Interest: The stock has a short interest of 6.49% of the float, which could lead to volatility if the stock rallies.
• •Recent Misses: The company has reported losses in recent quarters, including a Q3 loss of $4.3 million and a Q4 loss of $3.4 million.
• •Regulatory Hurdles: The FDA has previously issued a Complete Response Letter (CRL) for tab-cel, and the company faces challenges in securing approval.